Kellsye P Fabian

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Combination Therapy

Palliative Care

Top Venues

Cancer biology & therapy

Journal for immunotherapy of cancer

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
Ginette S Santiago-Sanchez, Kellsye P Fabian, James W Hodge
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer biology & therapy 25 (1) (2024)
S Elizabeth Franks, Ginette S Santiago-Sanchez, Kellsye P Fabian, Kristen Solocinski, Paul L Chariou, Duane H Hamilton, Joshua T Kowalczyk, Michelle R Padget, Sofia R Gameiro, Jeffrey Schlom, James W Hodge
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12. Cancer immunology, immunotherapy : CII (2023)
S Elizabeth Franks, Kellsye P Fabian, Ginette S Santiago-Sanchez, Benjamin Wolfson, James W Hodge
Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models. Oncoimmunology 11 (1) (2022)
Joshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, Diana C Lopez, Austin Tk Hoke, Clint T Allen, Mario Hermsen, Nyall R London, James W Hodge
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies. Journal for immunotherapy of cancer 10 (12) (2022)
Joshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, Diana C Lopez, Austin Tk Hoke, Clint T Allen, Mario Hermsen, Nyall R London, James W Hodge
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies. Journal for immunotherapy of cancer 10 (12) (2022)
Joshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, Diana C Lopez, Austin Tk Hoke, Clint T Allen, Mario Hermsen, Nyall R London, James W Hodge
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies. Journal for immunotherapy of cancer 10 (12) (2022)
Kellsye P Fabian, Michelle R Padget, Rika Fujii, Jeffrey Schlom, James W Hodge
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. Journal for immunotherapy of cancer 9 (2) (2021)
Kellsye P Fabian, Anthony S Malamas, Michelle R Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii, Houssein Abdul Sater, Jeffrey Schlom, James W Hodge
Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. Cancer immunology research 9 (2) (2020)